Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation

Clinical Cancer Research

Volumn 15, Issue 6, 2009, Pages 2058-2066

  Roidl, Andreas ^a   Berger, Hans Jürgen ^a   Kumar, Sushi ^a   Bange, Johannes ^b   Knyazev, Pjotr ^a   Ullrich, Axel ^a  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b U3 Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL XL; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL CLONE; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

BCL-X PROTEIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FIBROBLAST GROWTH FACTORS; HUMANS; MAP KINASE SIGNALING SYSTEM; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4; RNA, MESSENGER; UP-REGULATION;

EID: 63449138706     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0890     Document Type: Article

References (49)

1. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001; 7:548-52.
2. Fisher B, BryantJ, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002;20:4141-9.
3. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000;18: 1558-69.
4. Linn SC, Pinedo HM, van Ark-Otte J, et al. Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer1997;71:787-95.
5. Hudziak RM, Lewis GD, Holmes WE, Ullrich A, Shepard HM. Selection for transformation and met protooncogene amplification in NIH3T3 fibroblasts using tumor necrosis factor a. Cell Growth Differ 1990;1:129-34.
6. Abraham R, Schaefer J, Rothe M, Bange J, Knyazev P, Ullrich A. Identification of MMP-15asananti-apoptotic factor in cancer cells. J Biol Chem 2005;280:34123-32.
7. Eswarakumar VP, LaxI, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005;16:139-49.
8. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:3005.
9. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.
10. Koziczak M, Hynes NE. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin D1 translation. J Biol Chem 2004;279: 50004-11.
11. Shaoul E, Reich-Slotky R, Berman B, Ron D. Fibro-blast growth factor receptors display both common and distinct signaling pathways. Oncogene 1995;10:1553-61.
12. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 2005;16:233-47.
13. Bange J, Prechtl D,Cheburkin Y,et al. Cancerprogression and tumor cell motility are associated with the FGFR4Arg(388) allele. Cancer Res 2002;62:840-7.
14. Muenke M, Schell U. Fibroblast-growth-factor receptor mutations in human skeletal disorders. Trends Genet 1995;11:308-13.
15. Giri D, Ropiquet F, Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin Cancer Res1999;5:1063-71.
16. Yamaguchi F, Saya H, Bruner JM, Morrison RS. Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas. Proc Natl Acad Sci U S A1994;91:484-8.
17. Trudel S, Ely S, Farooqi Y, et al. Inhibition of fibroblast growth factorreceptor3 induces differentiation andap-optosisin t(4;14) myeloma. Blood 2004;103:3521-8.
18. 388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004;10:6169-78.
19. Jaakkola S, Salmikangas P, Nylund S, et al. Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer1993;54:378-82.
20. Penault-Llorca F, Bertucci F, Adelaide J, et al. Expression of FGF and FGF receptor genes in human breast cancer. IntJ Cancer1995;61:170-6.
21. Rhodes DR,Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
22. Kops GJ,Weaver BA, Cleveland DW. On theroad to cancer: aneuploidy and the mitotic checkpoint. Nat RevCancer 2005;5:773-85.
23. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res 2005;304:417-31.
24. EzzatS,Yu S, Asa SL. Ikaros isoformsin human pituitary tumors: distinct localization, histone acetylation, and activation of the 5′ fibroblast growth factor receptor-4promoter. Am J Pathol 2003;163:1177-84.
25. Shah RN, Ibbitt JC, Alitalo K, Hurst HC. FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1 a. Oncogene 2002;21:8251-61.
26. Yu S, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 is a target for the zinc-finger transcription factor Ikaros in the pituitary. Mol Endocrinol 2002;16:1069-78.
27. Yamada SM, Yamada S, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K. Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurol Res 2002;24:244-8.
28. Gowardhan B, Douglas DA, Mathers ME, et al. Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer. Br J Cancer 2005;92:320-7.
29. Reardon W, Winter RM, Rutland P, Pulleyn LJ, Jones BM, Malcolm S. Mutations in the fibroblast growth factor receptor 2 gene cause Crouzon syndrome. Nat Genet1994;8:98-103.
30. Schell U, Hehr A, Feldman GJ, et al. Mutations in FGFR1 and FGFR2 cause familial and sporadic Pfeiffer syndrome. Hum Mol Genet1995;4:323-8.
31. Shiang R, Thompson LM, Zhu YZ, et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 1994;78:335-42.
32. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammaryepithelial cell model. JCell Biol 2005;171:663-73.
33. Hart KC, Robertson SC, Donoghue DJ. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol Biol Cell 2001;12:931-42.
34. Hart KC, Robertson SC, Kanemitsu MY, MeyerAN, Tynan JA, Donoghue DJ. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000;19:3309-20.
35. Zhu L, Somlo G, Zhou B, et al. Fibroblast growth factor receptor 3 inhibition by short hairpin RNAs leads to apoptosis in multiple myeloma. Mol Cancer Ther 2005;4:787-98.
36. Xie MH, Holcomb I, Deuel B, et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine1999;11:729-35.
37. Olopade OI, Adeyanju MO, Safa AR, et al. Overexpression of BCL-xprotein in primary breast cancer is associated with high tumor grade and nodal metastases. CancerJ Sci Am 1997;3:230-7.
38. PenaJC,Thompson CB, RecantW,Vokes EE, Rudin CM. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-70.
39. Watanabe J, Kushihata F, Honda K, et al. Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004;135:604-12.
40. Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005;96:287-95.
41. Luo D, Cheng SC, Xie H, XieY Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line. Biochem Cell Biol 2000; 78:119-26.
42. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
43. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
44. Kochendoerfer SK, Krishnan N, Buckley DJ, Buckley AR. Prolactin regulation of Bcl-2 family members: increased expression of bcl-xL but not mcl-1 or bad in Nb2-T cells. J Endocrinol 2003; 178:265-73.
45. Yu S, Zheng L, Asa SL, Ezzat S. Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. Am J Physiol Endocrinol Metab 2002;283:E490-5.
46. Olie RA, Hafner C, Kuttel R, et al. Bcl-2 and bclxL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002;118:505-12.
47. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, Smythe WR. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma. Mol Cancer Ther 2004;3:545-50.
48. Simoes-Wust AP, Schurpf T, Hall J, Stahel RA, Zangemeister-Wittke U. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide. Breast Cancer Res Treat 2002;76:157-66.
49. Wang S, Yang D, Lippman ME. Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. Semin Oncol 2003;30:133-42.